Premium
First US experience following FDA approval of the ABBOTT vascular bioresorbable vascular scaffold for the treatment of coronary artery disease
Author(s) -
Rizik David G.,
Shah Maulik G.,
Burke Robert F.
Publication year - 2016
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.26708
Subject(s) - medicine , coronary artery disease , percutaneous , scaffold , stent , percutaneous coronary intervention , surgery , cardiology , myocardial infarction , biomedical engineering
Drug eluting stents are considered the “gold standard” for the percutaneous treatment of coronary artery disease. Recent publications have suggested that a reasonable alternative, in well selected cases, may be the ABSORBTM bioresorbable vascular scaffold (BVS) stent. © 2016 Wiley Periodicals, Inc.